May 5 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
VERTEX PHARMACEUTICALS Q1 ADJUSTED EPS $4.06 VERSUS IBES ESTIMATE $4.32
VERTEX PHARMACEUTICALS Q1 TOTAL REVENUE $2.77 BILLION VERSUS IBES ESTIMATE $2.85 BILLION
VERTEX PHARMACEUTICALS OUTLOOK 2025 TOTAL REVENUE $11.85 BILLION TO $12.0 BILLION VERSUS IBES ESTIMATE OF $11.97 BILLION
VERTEX PHARMACEUTICALS: 2025 GUIDANCE INCLUDES AN IMMATERIAL COST IMPACT FROM TARIFFS
VERTEX PHARMACEUTICALS: INTANGIBLE ASSET IMPAIRMENT CHARGE OF $379.0 MILLION ASSOCIATED WITH VX-264 IN Q1
Further company coverage: VRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.